GNUV201 / GENUV - LARVOL DELTA

GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy. (PubMed, BMC Immunol) - "In summary, GNUV201 exhibited enhanced affinity for PD-1 with slow dissociation and preferential binding in TME-mimicking low pH. Human/monkey/mouse inter-species cross-reactivity of GNUV201 could enable more predictable and translatable efficacy and toxicity preclinical studies. These results suggest that GNUV201 could be an ideal antibody candidate for anti-cancer drug development."

Journal • Preclinical • Oncology

GNUV205, a bifunctional protein of engineered IL-2 fused with a novel anti-PD1 antibody, exhibits superior tumor suppressing efficacy in vivo (SITC 2023) - "Methods GNUV205 is an investigational immuno-cytokine molecule which comprises anti-PD-1 antibody (GNUV201) and engineered IL-2 (interleukin-2). We also confirmed GNUV205’s excellent tumor suppressing efficacy in other syngeneic tumor models such as B16F10 and Pan02. Conclusions In summary, these data strongly suggest that GNUV205 is a candidate-stage bifunctional immuno-cytokine for solid cancer therapy expected to overcome the limitations of current standard-of-care therapies, such as IL-2 or anti-PD-(L)1s."

Preclinical • Oncology • Solid Tumor • FCGR2A • FCGR2B • IL2 • IL2RG

GNUV201, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer immunotherapy (SITC 2022) - "GNUV201 was also shown to completely block the interaction of hPD-1 with hPD-L1 in vitro at similar single digit nM levels compared with Keytruda and Opdivo, which results in enhanced T cell proliferation and cytokine (IL-2 and INF-g) secretion. Conclusions In summary, even though similar in vitro efficacy of GNUV201, we can expect GNUV201 to be an excellent antibody candidate with superior target occupancy due to its slow dissociation and preferential binding in low pH tumor microenvironments and whose efficacy and toxicity in the human system can be predicted from preclinical study results due to its human-mouse cross-reactivity."

Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Solid Tumor • IL2

GNUV201, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer immunotherapy. (ASCO 2022) - " GNUV201 equally binds to mouse and human PD-1 (EC50= 32 pM and 28 pM, respectively), while marketed Keytruda and Opdivo bind only to human PD-1. In summary, we expect GNUV201 to be an excellent antibody candidate whose efficacy and toxicity in the human system can be predicted from preclinical study results due to its human-mouse cross-reactivity and whose efficacy can be further improved with better target occupancy due to its slower dissociation and preferential binding in low pH tumor microenvironments. We are currently engineering GNUV201 to further improve antigen binding kinetics, which could lead to enhanced efficacy and pharmacokinetics in humans, and to develop the best-in-class PD-1 antibody based on superior comparative data from on-going efficacy studies."

Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Solid Tumor

Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June (Businesswire) - "Genuv Inc...announced it will release new preclinical data at two major medical conferences in June. 'We are excited to share new preclinical data for our two drug candidates, SNR1611 and GNUV201,' said Heung-rok Park, Ph.D., chief technology officer of Genuv."

Preclinical • Oncology • Solid Tumor

Genuv Teams With Nanocarry Therapeutics to Develop Novel anti-PD-1 mAb Treatments That Can Cross the Blood-Brain Barrier (Businesswire) - "Genuv Inc...and Nanocarry Therapeutics...announced an agreement to collaborate on the development of an experimental drug to treat metastatic lung cancer. Specifically, this collaboration will further develop GNUV201 to treat metastatic tumors in the brain, using Nanocarry’s AxS platform to cross the BBB....The two firms have applied for a grant from the Korea-Israel Industrial R&D Foundation (KORIL-RDF) to support an initial feasibility study including in vitro and in vivo studies to explore targeting the brain with antibodies to treat tumors."

Financing • Licensing / partnership • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor